TTI2

Across TCGA pan-cancer cohorts, TTI2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TTI2 data layer compared with 19 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TTI2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TTI2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where TTI2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	26	view →
PDAC	DFS	Tertile	All	0.519	0.209	.001	13	view →
LUAD	DFS	Median	All	0.470	0.893	.003	8	view →
LSCC	OS	Quartile	II,III,IV	0.933	0.511	.004	7	view →
HNSC	DFS	Quartile	III,IV	0.978	0.355	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TTI2–CCRCC (DFS)

Open the CCRCC breakdown →